Updates on OvaSuite®, OvaWatchSM, and EndoCheckTM Discussed in Fireside Chat with CEO| Nicole Sandford, CEO, Aspira Women's Health Inc. 00:10:00

Share On Facebook Share On Twitter

Aspira's CEO, Nicole Sandford, participated in a fireside chat with Sally Yanchus of Water Tower Research, LLC, discussing recent updates on clinical interest in OvaSuite® ovarian cancer risk assessment tests, the use of OvaWatchSM in serial monitoring of patients with adnexal masses, and the commercial availability of EndoCheckTM, a diagnostic test for endometriosis, following the publication of three abstracts at the ASCO meeting.

Recent Videos